Search

Ferric chloride

Cefixime

[A263031] Cefixime was first approved in the United States in 1986.[L49293] … [A232920, A232925, A232930] Cefixime is a broad-spectrum antibiotic and an orally-active third-generation semisynthetic cephalosporin.

Pentoxyverine

It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists [A32160]. … Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant [A32717], and local anesthetic properties.

Dutasteride

It is a novel dual 5α-reductase inhibitor that works by blocking both isoforms of 5α-reductase enzymes in a potent, selective, and irreversible manner. … Its clinical efficacy against benign prostate hyperplasia in male patients is comparable to that of [finasteride], a specific type II 5α-reductase inhibitor.

Bronopol

First synthesized in 1897, bronopol was primarily used as a preservative for pharmaceuticals and was registered in the United States in 1984 for use in industrial bactericides, slimicides and preservatives … L4873] and in other products where it may not primarily be used in the role of a non-medicinal preservative antimicrobial [L4874].

Empagliflozin

in 2014. … Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart

Colestipol

[FDA Label, F4555, F4567, L6262] In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces … Bile acid sequestrants like colestipol have been in use since the 1970s.

Pirfenidone

[A251370] It is an antifibrotic agent with anti-inflammatory and antioxidant properties [A251370] that is used to treat idiopathic pulmonary fibrosis (IPF),[L26801] which is a chronic, progressive form … Pirfenidone is a synthetic pyridone drug.

Levoleucovorin

This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted when high-dose methotrexate is used for cancer therapy. … However, in order to function in this role, it must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF).

Afamelanotide

[A187202,A187205] Afamelanotide is currently the only approved drug therapy used in the management of erythropoietic protoporphyria, having received approval in the EU in December 2014[L9119] and subsequent … FDA approval in October 2019.